Pemafibrate for treating MASLD complicated by hypertriglyceridaemia: a multicentre, open-label, randomised controlled trial study protocol
Authors: Iwaki Michihiro , Kobayashi Takashi , Nogami Asako , Ogawa Yuji , Imajo Kento , Sakai Eiji , Nakada Yoshinobu , Koyama Satoshi , Kurihashi Takeo , Oza Noriko , Kohira Toshikazu , Okada Michiaki , Yamaguchi Yuki , Iwane Shinji , Kageyama Fujito , Sasada Yuzo , Matsushita Masahiro , Tadauchi Akimitsu , Murohisa Gou , Nagasawa Masamichi , Sato Shuichi , Maeda Kazuhisa , Furuta Koichiro , Shigefuku Ryuta , Seko Yuya , Tobita Hiroshi , Kawata Kazuhito , Kawanaka Miwa , Sugihara Takaaki , Tamaki Nobuharu , Iwasa Motoh , Kawaguchi Takumi , Itoh Yoshito , Kawaguchi Atsushi , Takahashi Hirokazu , Nakajima Atsushi , Yoneda Masato 
Published: November 2024

Introduction

Non-alcoholic fatty liver disease, now known as metabolic dysfunction-associated steatotic liver disease (MASLD), is a phenotype of the metabolic syndrome in the liver and is clearly associated with metabolic abnormalities such as hyperglycaemia and dyslipidaemia. Although the prevalence of MASLD is increasing worldwide, there is currently no consensus on the efficacy and safety of the drugs used to treat MASLD/metabolic dysfunction-associated steatohepatitis (MASH). Pemafibrate, a selective peroxisome proliferator-activated receptor alpha modulator, was designed to have higher peroxisome proliferator-activated receptor alfa (PPARα) agonist activity and selectivity than existing PPARα agonists, and in development trials, without increasing creatinine levels, lipid parameters and alanine aminotransferase (ALT) were significantly improved. Thus, pemafibrate may effectively ameliorate the pathogenesis and metabolic abnormalities in MASLD/MASH. In this trial, we evaluated the efficacy and safety of pemafibrate in patients with MASLD/MASH.

Methods and analysis

This trial was designed as an open-label, three-arm, randomised controlled study. After obtaining informed consent, patients aged 20–80 years who met the selection criteria were enrolled. Patients were randomised to receive pemafibrate 0.4 mg/day, 0.2 mg/day or fenofibrate (n=120 per group). The duration of treatment was 48 weeks. The primary endpoint was a change in ALT levels after 24 weeks of administration. Secondary endpoints included changes from baseline in liver fibrosis markers (fibrosis-4 index, type IV collagen 7s, enhanced liver fibrosis and Mac-2 binding protein glycosylation isomer) at 48 weeks as well as changes in liver fat mass and liver stiffness measured by MRI and ultrasound (US) at centres equipped with MRI and US capabilities.

Ethics and dissemination

Ethical approval was obtained from the Yokohama City University Certified Institutional Review Board before participant enrolment (CRB20-014). The results of this study will be submitted for publication in international peer-reviewed journals and the key findings will be presented at international scientific conferences. Participants wishing to understand the results of this study will be contacted directly on data publication.

Trial registration number

This trial was registered in the Japan Registry of Clinical Trials (number: jRCTs031200280).

Protocol version

V.1.9, 23 November 2023